Effects of streptococcus thermophilus TH-4 in a rat model of doxorubicin-induced mucositis

Scandinavian Journal of Gastroenterology

Volumn 48, Issue 8, 2013, Pages 959-968

  Wang, Hanru ^a   Brook, Caitlin L ^a   Whittaker, Alexandra L ^a   Lawrence, Andrew ^b   Yazbeck, Roger ^c   Howarth, Gordon S ^a,d  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d Youth and Women's Health Service   (Australia)

Author keywords

Cancer; Chemotherapy; Doxorubicin; Mucositis; Probiotics; Streptococcus thermophilus

Indexed keywords

DOXORUBICIN; MYELOPEROXIDASE; PROBIOTIC AGENT; STREPTOCOCCUS THERMOPHILUS TH4; SUCRASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HISTOLOGY; MUCOSA INFLAMMATION; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; STREPTOCOCCUS THERMOPHILUS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL MARKERS; DOXORUBICIN; FEMALE; ILEUM; INJECTIONS, INTRAPERITONEAL; JEJUNUM; MUCOSITIS; PEROXIDASE; PROBIOTICS; RANDOM ALLOCATION; RATS; STREPTOCOCCUS THERMOPHILUS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84880426593     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2013.812142     Document Type: Article

References (45)

1. Pico JL, Avila-Garavito A, Naccache P. Mucositis: Its occurrence, consequences, and treatment in the oncology setting. Oncologist 1998;3:446-51.
2. Clarke JM, Pelton NC, Bajka BH, Howarth GS, Read LC, Butler RN. Use of the 13C-sucrose breath test to assess chemotherapy-induced small intestinal mucositis in the rat. Cancer Biol Ther 2006;5:34-8.
3. Avritscher EB, Cooksley CD, Elting LS. Scope and epidemiology of cancer therapy-induced oral and gastrointestinal mucositis. Semin Oncol Nurs 2004;20:3-10.
4. Bowen JM, Gibson RJ, Cummins AG, Keefe DM. Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. Support Care Cancer 2006; 14:713-31.
5. Keefe DM, Gibson RJ, Hauer-Jensen M. Gastrointestinal mucositis. Semin Oncol Nurs 2004;20:38-47.
6. Wright TH, Yazbeck R, Lymn KA, Whitford EJ, Cheah KY, Butler RN, et al. The herbal extract, Iberogast, improves jejunal integrity in rats with 5-Fluorouracil (5-FU)-induced mucositis. Cancer Biol Ther 2009;8:923-9.
7. Cheah KY, Howarth GS, Yazbeck R, Wright TH, Whitford EJ, Payne C, et al. Grape seed extract protects IEC-6 cells from chemotherapy-induced cytotoxicity and improves parameters of small intestinal mucositis in rats with experimentally-induced mucositis. Cancer Biol Ther 2009;8:382-90.
8. Torres DM, Tooley KL, Butler RN, Smith CL, Geier MS, Howarth GS. Lyprinol only partially improves indicators of small intestinal integrity in a rat model of 5-fluorouracilinduced mucositis. Cancer Biol Ther 2008;7:295-302.
9. Howarth GS, Francis GL, Cool JC, Xu X, Byard RW, Read LC. Milk growth factors enriched from cheese whey ameliorate intestinal damage by methotrexate when administered orally to rats. J Nutr 1996;126:2519-30.
10. Yazbeck R, Howarth GS, Borges L, Geier MS, Smith CL, Davidson GP, et al. Non-invasive detection of a paliferminmediated adaptive response following chemotherapyinduced damage to the distal small intestine of rats. Cancer Biol Ther 2011;12:399-406.
11. Tooley KL, Howarth GS, Lymn KA, Lawrence A, Butler RN. Oral ingestion of Streptococcus thermophilus diminishes severity of small intestinal mucositis in methotrexate treated rats. Cancer Biol Ther 2006;5:593-600.
12. Whitford EJ, Cummins AG, Butler RN, Prisciandaro LD, Fauser JK, Yazbeck R, et al. Effects of Streptococcus thermophilus TH-4 on intestinal mucositis induced by the chemotherapeutic agent, 5-Fluorouracil (5-FU). Cancer Biol Ther 2009;8:505-11.
13. Howarth GS. Probiotic-derived factors: probiotaceuticals? J Nutr 2010;140:229-30.
14. Nissen L, Chingwaru W, Sgorbati B, Biavati B, Cencic A. Gut health promoting activity of new putative probiotic/protective Lactobacillus spp. strains: a functional study in the small intestinal cell model. Int J Food Microbiol 2009; 135:288-94.
15. Stringer AM, Gibson RJ, Bowen JM, Logan RM, Yeoh AS, Keefe DM. Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment. J Support Oncol 2007;5:259-67.
16. O'Sullivan GC, Kelly P, O'Halloran S, Collins C, Collins JK, Dunne C, et al. Probiotics: An Emerging Therapy. Curr Pharm Design 2005;11:3-10.
17. Saulnier N, Zocco MA, Di Caro S, Gasbarrini G, Gasbarrini A. Probiotics and small bowel mucosa: Molecular aspects of their interactions. Genes Nutr 2006;1:107-15.
18. Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am 1997;23:739-55.
19. Crittenden RG, Martinez NR, Playne MJ. Synthesis and utilisation of folate by yoghurt starter cultures and probiotic bacteria. Int J Food Microbiol 2003;80:217-22.
20. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8.
21. Howarth GS, Tooley KL, Davidson GP, Butler RN. A noninvasive method for detection of intestinal mucositis induced by different classes of chemotsherapy drugs in the rat. Cancer Biol Ther 2006;5:1189-95.
22. Thomas DJ, Caffrey TC. Lipopolysaccharide induces doublestranded DNA fragmentation in mouse thymus: protective effect of zinc pretreatment. Toxicology 1991;68:327-37.
23. Eutamene H, Lamine F, Chabo C, Theodorou V, Rochat F, Bergonzelli GE, et al. Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats. J Nutr 2007; 137:1901-7.
24. Howarth GS, Wang H. Role of endogenous microbiota, probiotics and their biological products in human health. Nutrients 2013;5:58-81.
25. Mohan P, Rapoport N. Doxorubicin as a molecular nanotheranostic agent: effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound-mediated intracellular delivery and nuclear trafficking. Mol Pharm 2010;7:1959-73.
26. El-Sayyad HI, Ismail MF, Shalaby FM, Abou-El-Magd RF, Gaur RL, Fernando A, et al. Histopathological effects of cisplatin, doxorubicin and 5-flurouracil (5-FU) on the liver of male albino rats. Int J Biol Sci 2009;5:466-73.
27. Ibrahim MA, Ashour OM, Ibrahim YF, El-Bitar HI, Gomaa W, Abdel-Rahim SR. Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol Res 2009;60:373-81.
28. Esposito E, Iacono A, Bianco G, Autore G, Cuzzocrea S, Vajro P, et al. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. J Nutr 2009;139:905-11.
29. Sultana R, Di Domenico F, Tseng M, Cai J, Noel T, Chelvarajan RL, et al. Doxorubicin-Induced Thymus Senescence. J Proteome Res 2010;9:6232-41.
30. Normann SJ, Weiner R. Cytotoxicity of human peripheral blood monocytes. Cell Immunol 1983;81:413-25.
31. Unger SW, Bernhard MI, Pace RC, Wanebo JH. Monocyte Dysfunction in Human. Cancer. Cancer 1983;51:669-74.
32. Nakata Y, Yamashita J, Kishi T, Kataoka M, Ejiri T, Ohnoshi T, et al. Decreased monocyte-mediated cytostasis of human cancer cell in patients with lung cancer. Cancer Immunol Immunother 1985;20:43-6.
33. Powell CB, Mutch DG, Kao MS, Collins JL. Reduced natural cytotoxic cell activity in patients receiving cisplatinbased chemotherapy and in mice treated with cisplatin. Clin Exp Immunol 1990;79:424-9.
34. Kleinerman ES, Zwelling LA, Howser D, Barlock A, Young RC, Decker JM, et al. Defective monocyte killing in patients with malignancies and restoration of function during chemotherapy. Lancet 1980;2:1102-5.
35. Sheih YH, Chiang BL, Wang LH, Liao CK, Gill HS. Systemic immunity-enhancing effects in healthy subjects following dietary consumption of the lactic acid bacterium Lactobacillus rhamnosus HN001. J Am Coll Nutr 2001; 20:149-56.
36. Menard S, Candalh C, Bambou JC, Terpend K, Cerf-Bensussan N, Heyman M. Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport. Gut 2004;53:821-8.
37. Perdigon G, Maldonado Galdeano C, Valdez JC, Medici M. Interaction of lactic acid bacteria with the gut immune system. Eur J Clin Nutr 2002;56:S21-6.
38. Chiang BL, Sheih YH, Wang LH, Liao CK, Gill HS. Enhancing immunity by dietary consumption of a probiotic lactic acid bacterium (Bifidobacterium lactis HN019): optimization and definition of cellular immune responses. Eur J Clin Nutr 2000;54:849-55.
39. Kotzamanidis C, Kourelis A, Litopoulou-Tzanetaki E, Tzanetakis N, Yiangou M. Evaluation of adhesion capacity, cell surface traits and immunomodulatory activity of presumptive probiotic Lactobacillus strains. Int J Food Microbiol 2010;140:154-63.
40. Hidemura A, Saito H, Fukatsu K, Matsuda T, Kitayama J, Ikeda S, et al. Oral administration of Bifidobacterium longum culture condensate in a diet-restricted murine peritonitis model enhances polymorphonuclear neutrophil recruitment into the local inflammatory site. Nutrition 2003;19:270-4.
41. Sheehy TW, Baggs B, Perez-Santiago E, Floch MH. Prognosis of tropical sprue. A study of the effect of folic acid on the intestinal aspects of acute and chronic sprue. Ann Intern Med 1962;57:892-908.
42. Wang S, Low PS. Folate-mediated targeting of antineoplastic drugs, imaging agents, and nucleic acids to cancer cells. J Control Release 1998;53:39-48.
43. Germann WJ, Stanfield CL. Principles of human physiology. San Francisco, CA: Benjamin Cummings; 2001.
44. Keefe DM, Brealey J, Goland GJ, Cummins AG. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 2000;47:632-7.
45. Mauger CA, Butler RN, Geier MS, Tooley KL, Howarth GS. Probiotic effects on 5-fluorouracil-induced mucositis assessed by the sucrose breath test in rats. Dig Dis Sci 2007;52:612-19.